Keerthi Talari

Keerthi Talari

Auto-generated profile, based on publicly available information

Keerthi Talari


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 March 2025 in Best Practice & Research Clinical Rheumatology
Verified
Journal Article
Closed access
KTKeerthi Talari
Keerthi Talari
HPHimanshu Pathak
Himanshu Pathak
NJNeeraj Jain
Neeraj Jain
VRVinod Ravindran
Vinod Ravindran

24 November 2023 in Journal of the Royal College of Physicians of Edinburgh
Verified
Journal Article
Closed access
KTKeerthi Talari
Keerthi Talari
VRVinod Ravindran
Vinod Ravindran
Predatory publishing poses a major threat to the integrity of academic research. While publication in scientific journals has traditionally been a hallmark of authentic information, the 'publish or perish' culture has fuelled and enhanced the growth of predatory journals. Predatory publishers prioritise profit over academic integrity, often charge exorbitant fees for a nearly non-existent peer review. Lack of awareness, pressure to publish and the prohibitive cost of open-access publishing contribute to the dubious cause of predatory journals. Identifying predatory journals is essential, and multiple resources exist to assist in identifying them.

11 December 2025 in Osteoarthritis and Cartilage Open
Verified
Journal Article
Open access
PGPawan Kumar Gupta
Pawan Kumar Gupta
SMSunil Maheshwari
Sunil Maheshwari
JCJoe Joseph Cherian
Joe Joseph Cherian
VGVijay Goni
Vijay Goni
ASArun Kumar Sharma
Arun Kumar Sharma
UKUday Kumar
Uday Kumar
The aim of this study was to assess whether allogeneic cultured, pooled, bone marrow derived mesenchymal stromal cells (BMMSCs), has potential to impact progression of osteoarthritis (OA). Randomized, double blind, multicentric, placebo-controlled trial to assess efficacy and safety of BMMSCs in Grade 2 and 3 OA of knee. 146 patients were randomized, 73 patients each received either BMMSCs (25 million cells) or placebo followed by 20 mg HA. The primary end point was evaluation of WOMAC Composite Index and secondary end points were WOMAC sub-scores, VAS, magnetic resonance (MR) assessment (T2 mapping and cartilage volume). 58 patients from BMMSC arm and 60 patients from placebo arm completed 24 months follow-up. At 24 months follow up, WOMAC composite index and WOMAC sub scores showed significant improvements in cell arm as compared to placebo (p < 0.0001); T2 mapping showed there is no worsening of the cartilage in the medial femoral tibial compartment in BMMSC arm whereas placebo arm shows gradual worsening (p < 0.0001). Cartilage volume increased in BMMSC arm. At Day 90 & 730, Urinary C – terminal cross linked telopeptide of type II collagen significantly decreased in the cell arm and increased in the placebo arm (p-value<0.0001). 5 AEs were possibly related to the study drug and were local site administration effects. By 24 months follow-up, 4 patients in the placebo group underwent TKR versus 1 patient in the BMMSC arm. This study demonstrates that BMMSC's is safe and effective for the treatment of grade 2 & 3 OA of knee. CTRI/2018/09/015785 [Registered on: September 20, 2018]

29 July 2016 in MOJ Orthopedics & Rheumatology
Verified
Journal Article
Open access
PDF file
KTKeerthi Talari
Keerthi Talari
With the introduction of biologics, there has been significant improvement in response in rheumatologic disorders like rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. As most of these biologics have approached patent expiry, follow on versions called biosimilars have been introduced. Though only two of them have been approved by the EMA and one by the FDA, quite a few have been introduced in India. The process of approval of bio similars requires strict regulations to demonstrate efficacy, purity and safety. Preclinical, clinical (pharmacokinetic, pharmacodynamics, efficacy and safety) studies are to be done before their approval. Currently, five biosimilars used in rheumatology are approved in India. This review discusses the process of development of a biosimilar, regulatory guidelines in their approval process in India and the current status of biosimilars in rheumatology in India.

23 May 2025 in Rheumatology
Verified
Journal Article
Closed access
KTKeerthi Talari
Keerthi Talari
VRVinod Ravindran
Vinod Ravindran

17 June 2025 in International Journal of Rheumatic Diseases
Verified
Journal Article
Closed access
KTKeerthi Talari
Keerthi Talari
SESamar Al Emadi
Samar Al Emadi
VRVinod Ravindran
Vinod Ravindran